Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kezar Life Sciences Inc KZR

Healthcare Biotechnology
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical... see more

Recent & Breaking News (NDAQ:KZR)

Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis

Business Wire October 23, 2020

Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences

Business Wire October 15, 2020

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

Business Wire September 17, 2020

Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology

Business Wire September 10, 2020

Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

Business Wire August 5, 2020

Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences

Business Wire August 3, 2020

Kezar Life Sciences to Release Second Quarter Financial Results and General Business Updates on August 5, 2020

Business Wire July 29, 2020

Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants

GlobeNewswire June 8, 2020

Kezar Announces Proposed Public Offering of Common Stock

GlobeNewswire June 8, 2020

Kezar Provides Data Update from MISSION Study of KZR-616

GlobeNewswire June 3, 2020

Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference

GlobeNewswire May 28, 2020

Kezar Announces Presentations During Upcoming Scientific Conferences

GlobeNewswire May 20, 2020

Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire May 7, 2020

Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer

GlobeNewswire May 4, 2020

Kezar Provides Statement Regarding COVID-19 Pandemic

GlobeNewswire April 9, 2020

Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update

GlobeNewswire March 12, 2020

Kezar Life Sciences to Present at Cowen and Company's 40th Annual Healthcare Conference

GlobeNewswire February 26, 2020

Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire February 4, 2020

Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 31, 2020

Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 30, 2020